Market capitalization | $20.81m |
Enterprise Value | $-77.92m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.79 |
P/B ratio (TTM) P/B ratio | 0.25 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-121.40m |
Free Cash Flow (TTM) Free Cash Flow | $-98.47m |
Cash position | $100.14m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
6 Analysts have issued a Athira Pharma Inc forecast:
6 Analysts have issued a Athira Pharma Inc forecast:
Jun '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.97 -0.97 |
17%
17%
|
|
EBITDA | -120 -120 |
12%
12%
|
EBIT (Operating Income) EBIT | -121 -121 |
12%
12%
|
Net Profit | -113 -113 |
5%
5%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Athira Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. The company was founded by Leen Kawas and Joseph Harding in 2011 and is headquartered in Seattle, WA.
Head office | United States |
CEO | Mark Litton |
Employees | 67 |
Founded | 2011 |
Website | www.athira.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.